

=====

Sequence Listing could not be accepted due to errors.  
See attached Validation Report.  
If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).  
Reviewer: Anne Corrigan  
Timestamp: [year=2010; month=7; day=19; hr=10; min=51; sec=33; ms=7; ]  
=====

\*\*\*\*\*

Reviewer Comments:

<210> 54  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> polylysine sequence

<400> 54

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

As an explanation of "<213> Artificial Sequence", the above <223>  
response needs more information regarding the source of the genetic  
material: it is obvious that this is a polylysine sequence. Same in  
the <223> response in Sequence 62.

<160> 50

<210> 62  
<211> 27  
<212> DNA  
<213> Artificial Sequence

Although the above <160> response is "50", there are 62 sequences in the  
submitted file.

\*\*\*\*\*

Application No: 10559758 Version No: 2.0

**Input Set:****Output Set:**

**Started:** 2010-07-16 13:05:09.442  
**Finished:** 2010-07-16 13:05:13.391  
**Elapsed:** 0 hr(s) 0 min(s) 3 sec(s) 949 ms  
**Total Warnings:** 62  
**Total Errors:** 2  
**No. of SeqIDs Defined:** 50  
**Actual SeqID Count:** 62

Error code	Error Description
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <141>
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)

**Input Set:**

**Output Set:**

**Started:** 2010-07-16 13:05:09.442  
**Finished:** 2010-07-16 13:05:13.391  
**Elapsed:** 0 hr(s) 0 min(s) 3 sec(s) 949 ms  
**Total Warnings:** 62  
**Total Errors:** 2  
**No. of SeqIDs Defined:** 50  
**Actual SeqID Count:** 62

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (20) This error has occurred more than 20 times, will not be displayed
E 252	Calc# of Seq. differs from actual; 50 seqIds defined; count=62

SEQUENCE LISTING

<110> Hart, Stephen Lewis  
Writer, Michele

<120> PEPTIDE LIGANDS

<130> ABL-012.1P US

<140> 10559758

<141> 2010-07-16

<150> PCT/EP2004/002421

<151> 2004-06-07

<150> GB 03 13132.3

<151> 2003-06-06

<160> 50

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = a  
ny amino acid residue, Xaa at position 4 = any amino acid residue

<400> 1

Pro Xaa Xaa Xaa Thr  
1 5

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells  
<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> Xaa at position 3 = any amino acid residue

<400> 2

Pro Ser Xaa Ser  
1

<210> 3

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells  
<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid, Xaa at position 3 = any amino

acid having an amide side chain, Xaa at position 4 = any amino acid

<400> 3

Gln Xaa Xaa Xaa Gln  
1 5

<210> 4

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue having an aliphatic side chain

<400> 4

Ser Xaa Ser  
1

<210> 5

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 5

Pro Xaa Leu Xaa Thr  
1 5

<210> 6

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 6

Pro Ala Leu Lys Thr  
1 5

<210> 7

<211> 5

<212> PRT

<213> Artificial Sequence

<220>



<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 7

Pro Xaa Asn Xaa Thr  
1 5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 8

Pro Ser Asn Ser Thr  
1 5

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 9

Pro Pro Asn Thr Thr  
1 5

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = any amino acid residue

<400> 10

Pro Xaa Xaa Xaa Thr Xaa  
1 5

<210> 11

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = any amino acid residue

<400> 11

Pro Xaa Leu Xaa Thr Xaa  
1 5

<210> 12

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = any amino acid residue

<400> 12

Pro Xaa Asn Xaa Thr Xaa  
1 5

<210> 13

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (3)..(5)

<223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue, Xaa at position 5 = any amino acid residue

<400> 13

Xaa Pro Xaa Xaa Xaa Thr  
1 5

<210> 14

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (3)..(5)

<223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue, Xaa at position 5 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> Xaa at position 7 = any amino acid residue

<400> 14

Xaa Pro Xaa Xaa Xaa Thr Xaa  
1 5

<210> 15

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 15

Ala Pro Ser Asn Ser Thr Ala  
1 5

<210> 16

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 16

Ser Pro Ala Leu Lys Thr Val  
1 5

<210> 17

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 17

Ser Thr Pro Pro Asn Thr Thr  
1 5

<210> 18

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 18

Pro Ser Asn Ser  
1

<210> 19

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 19

Pro Ser Leu Ser  
1

<210> 20

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = Ala or Lys

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 20

Xaa Pro Ser Xaa Ser

1 5

<210> 21

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 21



Ala Pro Ser Asn Ser  
1 5

<210> 22

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 22

Leu Pro Ser Leu Ser  
1 5

<210> 23

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 23

Met Leu Pro Ser Leu Ser  
1 5

<210> 24

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 24

Pro Met Leu Pro Ser Leu Ser  
1 5

<210> 25

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 25

Ser Gln Lys Asn Pro Gln Met  
1 5

<210> 26

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 26

Phe Gln Ser Gln Tyr Gln Lys  
1 5

<210> 27

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 27

Met Ala Ser Ile Ser Met Lys  
1 5

<210> 28

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 28

Asp Trp Trp His Thr Ser Ala  
1 5

<210> 29

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 29

Ser His Val Lys Leu Asn Ser  
1 5

<210> 30

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 30

Gln Leu Leu Thr Gly Ala Ser  
1 5

<210> 31

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 31

Thr Ala Arg Asp Tyr Arg Leu  
1 5

<210> 32

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 32

Phe Pro Arg Ala Pro His His  
1 5

<210> 33

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 33

Ser Glu Trp Leu Ser Ala Leu  
1 5

<210> 34

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 34

Ile Gly Gly Ile Arg Arg His  
1 5

<210> 35

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 35

Tyr Thr Met Glu Phe Asn Arg  
1 5

<210> 36

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 36

Pro Ala Ala Tyr Lys Ala His  
1 5

<210> 37

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = a  
ny amino acid residue, Xaa at position 4 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = Ala or Val

<400> 37

Pro Xaa Xaa Xaa Thr Xaa  
1 5

<210> 38

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue,

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue,

<400> 38

Pro Xaa Asn Xaa Thr  
1 5

<210> 39

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A  
sn or Leu, Xaa at position 4 = any amino acid residue

<400> 39

Pro Xaa Xaa Xaa Thr  
1 5

<210> 40

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position = Thr or Ser

<400> 40

Pro Xaa Asn Xaa Thr  
1 5



<210> 41

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = Ala or Leu

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 41

Xaa Pro Ser Xaa Ser

1 5

<210> 42

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A  
sn or Gln, Xaa at position 3 = any amino acid residue

<400> 42

Gln Xaa Xaa Xaa Gln  
1 5

<210> 43

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = Leu or Ile

<400> 43

Ser Xaa Ser  
1

<210> 44

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 44

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Ser His Val Lys Leu Asn Ser Cys Gly  
20 25

<210> 45

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 45

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Ala Pro Ser Asn Ser Thr Ala Cys Gly  
20 25

<210> 46

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 46

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gly

20 25

<210> 47

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 47

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Phe Pro Arg Ala Pro His His Cys Gly  
20 25

<210> 48

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 48

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Asp Trp Trp His Thr Ser Ala Cys Gly  
20 25

<210> 49

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 49

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly  
20 25

<210> 50

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 50

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Ala Thr Arg Trp Ala Arg Glu Cys Gly  
20 25

<210> 51

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 51

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Arg Arg Glu Glu Trp Ala Cys Gly

20

25

<210> 52

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 52

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gln  
20 25

<210> 53

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> integrin-binding peptide

<400> 53

Arg Arg Glu Thr Glu Trp Ala  
1 5

<210> 54

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> polylysine sequence

<400> 54

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

<210> 55

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> hydrophobic spacer sequence

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> x = epsilon-amino hexanoic acid residue

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> x = epsilon-amino hexanoic acid residue